ArticleFrontiers in immunology2019
CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival.
Article in Frontiers in immunology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Decoding TNF receptor superfamily control of CD4Cell communication and signaling : CCS · 2026Review
- Impact of Immune Cells on IgA Vasculitis via Metabolites and Inflammatory Cytokines.Journal of clinical immunology · 2025Article
- A donor PD-1Signal transduction and targeted therapy · 2025Article
- Pathogenetic development, diagnosis and clinical therapeutic approaches for liver metastasis from colorectal cancer (Review).International journal of oncology · 2025Review
- Exploring Molecular Drivers of PARPi Resistance in BRCA1-Deficient Ovarian Cancer: The Role of LY6E and Immunomodulation.International journal of molecular sciences · 2024Article
- An angel or a devil? Current view on the role of CD8Journal of translational medicine · 2024Review
- Renal graft function in transplanted patients correlates with CD45RC T cell phenotypic signature.PloS one · 2024Article
- ESAT-6 protein suppresses allograft rejection by inducing CD4Frontiers in immunology · 2024Article
- CD8Journal of clinical medicine · 2023Article
- Circulating CD8BMC cancer · 2022Article
- Dendritic Cell-Targeted Therapies to Treat Neurological Disorders.Molecular neurobiology · 2022Review
- Vasculitogenic T Cells in Large Vessel Vasculitis.Frontiers in immunology · 2022Review
- CD8Frontiers in immunology · 2021Review
- Newly Found Peacekeeper: Potential of CD8+ Tregs for Graft-Versus-Host Disease.Frontiers in immunology · 2021Review
- Regulatory T Cells: Concept, Classification, Phenotype, and Biological Characteristics.Advances in experimental medicine and biology · 2021Article
- Future prospects for CD8Immunological reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A transplanted organ is always rejected in the absence of any immunosuppressive treatment due to vigorous alloimmunity. However, continuously global immunosuppression with a conventional immunosuppressant may result in severe side effects, including nephrotoxicity, tumors and infections. Tregs have been widely used to inhibit allograft rejection, especially in animal models. However, it's well accepted that administration of Tregs alone is not satisfactory in immune-competent wild-type animals. Therefore, it's imperative to promote Treg therapies under the cover of other approaches, including costimulatory blockade. In the present study, we demonstrated that administration of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.